Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.12.18
Views: 134

Dr Victor Chow - Fred Hutchinson Cancer Research Centre, Seattle, USA

Dr Victor Chow speaks to ecancer at. ASH 2018 about outcomes of patients who have progression of their disease following CD19-specific CAR T-cell therapy.

He explains that there was a need for more data on this group of patients so they tried to delineate their outcomes and look at different predictors.

Dr Chow concludes that patients with early progression appear to be a high risk group and he hopes that this is data that will encourage more clinical trials for them.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation